Dose-ranging Study

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Dose ranging study

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neothetics, Inc
• Treatments: Fluticasone; Salmeterol Xinafoate; Xhance

Criteria

Inclusion Criteria:

• 18 - 45 years of age inclusive

• abdominal contour defect

• BMI <25 kg/msq

• Stable diet and exercise and body weight

Exclusion Criteria:

• Prior treatment of abdominal contour defects (liposuction, abdominoplasty, etc)

• Known hypersensitivity to study drugs